ASTRO '19: ViewRay to feature MRIdian, MRIdian linac

By News Release


ViewRay, Inc. announced that the company’s MRIdian® and MRIdian Linac MRI-guided radiation therapy systems will be featured at the 2019 Annual Meeting of the American Society for Radiation Oncology (ASTRO), September 15-19, 2019 in Chicago. The meeting will feature a number of presentations highlighting the unique capabilities, clinical experience and patient outcomes with ViewRay’s MRIdian and MRIdian Linac.

First pioneered by ViewRay in 2012, MRI-Guided ROAR™ (Real-time On-table Adaptive Radiotherapy) represents a new paradigm in cancer treatment. It provides clinicians with the ability to improve targeting precision and accuracy to deliver higher, and potentially more effective, radiation doses.

At this year’s ASTRO, more than 20 scientific session presentations/posters will highlight the important role of MRIdian in cancer treatment including the value of its MRI-guidance, targeted dose delivery and automated beam gating. With the added clarity provided by MRIdian real-time imaging, physicians are better equipped to account for any motion caused by respiration or other bodily processes and personalize each treatment. 

An ASTRO Industry Expert Theater session on Sunday, September 15 from 2:30 - 3:30 p.m. will feature two talks on the important role of MRIdian in the treatment of prostate and pancreatic cancer. The first by Ben Slotman, M.D., Ph.D., from Amsterdam University Medical Centers is titled “MR-Guided Daily Adaptive SBRT for Prostate Cancer - A Phase 2 Prospective Study,” and the second by Michael Chuong, M.D., from Miami Cancer Institute, Baptist Health South Florida is titled “MR-Guided SBRT for Pancreas with On-table Adaptation on MRIdian - MCI Experience.” 

ViewRay’s booth # 3016 will feature presentations from eight MRIdian users covering a wide range of topics and indications including: 

  • MR-Guided Online Adaptive Radiotherapy: Clinical Experience of National Cancer Center Hospital in Japan – Prof. Hiroshi Igaki, M.D., National Cancer Center Japan: Tsukiji Campus
  • SMART: Status Update on the First Prospective, Multi-Institutional Study on Ablative Pancreas SBRT – Parag Parikh, M.D., Henry Ford Health System
  • Real-time Targeting: A Necessity for High Precision RT of the Abdomen and Thorax  – John Bayouth, Ph.D., University of Wisconsin – Madison
  • MRI-Guided Liver Radiation: Seeing What You are Missing – Michael Bassetti, M.D., Ph.D., Carbone Cancer Center, University of Wisconsin – Madison
  • MRI-Guided Prostate RT: See the Cancer, Spare the Toxicity – Himanshu Nagar, M.D., The NewYork-Presbyterian Hospital and Weill Cornell Medicine
  • Liver MRI-Guided Stereotactic Body Radiation Therapy (SBRT) – Lorraine Portelance, M.D., Sylvester Comprehensive Cancer Center, University of Miami Health System
  • ViewRay SBRT of Prostate: Seeing is Believing – Prof. Jin Ho Kim, M.D., Seoul National University Hospital
  • Extreme Hypofractionated MR-Guided Partial Breast Treatments, Clinical Outcomes on MRIdian – Imran Zoberi, M.D., Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

For a schedule of in-booth presentations and events at ASTRO, or to book a product demonstration in advance, please visit Demos can also be booked on-site during ASTRO by visiting the registration desk within the ViewRay booth.

Back To Top

ASTRO '19: ViewRay to feature MRIdian, MRIdian linac.  Appl Rad Oncol. 

By News Release| September 10, 2019
Categories:  Section|Technologies

About the Author

News Release

News Release


Copyright © Anderson Publishing, Ltd

    Agility CMS